1. Hosainzadegan M, Aziz E, Rovshan K, Nasibova A, Amir H, Parviz V, et al. Are microbial infections and some antibiotics causes cancer. Adv Biol Earth Sci. 2020; 5: 58–61.

2. Ali I, Saleem K, Aboul-Enein HY, Rather A. Social Aspects of Cancer Genesis. Cancer Therapy. 2011; 8: 6–14.

3. Ali I, Wani WA, Khan A, Haque A, Ahmad A, Saleem K, et al. Synthesis and synergistic antifungal activities of a pyrazoline based ligand and its copper (II) and nickel (II) complexes with conventional antifungals. Microb Pathogenesis. 2012; 53: 66–73.

4. Ali I, Wani WA, Haque A, Saleem K. Glutamic acid and its derivatives: candidates for rational design of anticancer drugs. Future Med Chem. 2013; 5: 961–978.

5. Ali I, Wani WA, Saleem K, Hsieh M. Anticancer metallodrugs of glutamic acid sulphonamides: in silico, DNA binding, hemolysis and anticancer studies. Rsc Adv. 2014; 4: 29629–29641.

6. Angellotti G, Di Prima G, Belfiore E, Campisi G, De Caro V. Chemopreventive and Anticancer Role of Resveratrol against Oral Squamous Cell Carcinoma. Pharmaceutics. 2023; 15: 275.

7. Ahmadian E, Dizaj SM, Sharifi S, Shahi S, Khalilov R, Eftekhari A, et al. The potential of nanomaterials in theranostics of oral squamous cell carcinoma: Recent progress. Trac-Trend Anal Chem. 2019; 116: 167–176.

8. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca: A Cancer Journal for Clinicians. 2021; 71: 209–249.

9. Li H, Zhang Y, Xu M, Yang D. Current trends of targeted therapy for oral squamous cell carcinoma. J Cancer Res Clin. 2022; 148: 2169–2186.

10. Huang Y, Sun J, Li J, Zhu D, Dong M, Dou S, et al. Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial). Int J Surg. 2023; 109: 2220–2227.

11. Dai F, Dai L, Zheng X, Guo Y, Zhang Y, Niu M, et al. Non-coding RNAs in drug resistance of head and neck cancers: A review. Biomed Pharmacother. 2020; 127: 110231.

12. Nisar S, Yousuf P, Masoodi T, Wani NA, Hashem S, Singh M, et al. Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment. International Journal of Molecular Sciences. 2021; 22: 4584.

13. Niu Q, Sun Q, Bai R, Zhang Y, Zhuang Z, Zhang X, et al. Progress of Nanomaterials-Based Photothermal Therapy for Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences. 2022; 23: 10428.

14. Dai H, Yan H, Dong F, Zhang L, Du N, Sun L, et al. Tumor-targeted biomimetic nanoplatform precisely integrates photodynamic therapy and autophagy inhibition for collaborative treatment of oral cancer. Biomater Sci-Uk. 2022; 10: 1456–1469.

15. Ali I, A. Wani W, Saleem K, Haque A. Thalidomide: A Banned Drug Resurged into Future Anticancer Drug. Curr Drug Ther. 2012; 7: 13–23.

16. Ali I, Lone MN, Suhail M, Mukhtar SD, Asnin L. Advances in Nanocarriers for Anticancer Drugs Delivery. Curr Med Chem. 2016; 23: 2159.

17. Ali I, Lone MN, Alothman ZA, Alwarthan A. Insights into the pharmacology of new heterocycles embedded with oxopyrrolidine rings: DNA binding, molecular docking, and anticancer studies. J Mol Liq. 2017; 234: 391–402.

18. Ali I, Saleem K, Wesselinova D, Haque A. Synthesis, DNA binding, hemolytic, and anti-cancer assays of curcumin I-based ligands and their ruthenium (III) complexes. Med Chem Res. 2013; 22: 1386–1398.

19. Eftekhari A, Kryschi C, Pamies D, Gulec S, Ahmadian E, Janas D, et al. Natural and synthetic nanovectors for cancer therapy. Nanotheranostics. 2023; 7: 236–257.

20. Ali I, Alsehli M, Scotti L, Tullius Scotti M, Tsai S, Yu R, et al. Progress in polymeric nano-medicines for theranostic cancer treatment. Polymers-Basel. 2020; 12: 598.

21. Ju W, Xia R, Zhu D, Dou S, Zhu G, Dong M, et al. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. Nat Commun. 2022; 13: 5378.

22. Zheng D, Deng W, Song W, Wu C, Liu J, Hong S, et al. Biomaterial-mediated modulation of oral microbiota synergizes with PD-1 blockade in mice with oral squamous cell carcinoma. Nat Biomed Eng. 2022; 6: 32–43.

23. Kenison JE, Wang Z, Yang K, Snyder M, Quintana FJ, Sherr DH. The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation. Proceedings of the National Academy of Sciences. 2021; 118: e2012692118.

24. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17: 807–821.

25. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019; 18: 175–196.

26. Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022; 375: eabf9419.

27. Meylan M, Petitprez F, Becht E, Bougoüin A, Pupier G, Calvez A, et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity. 2022; 55: 527–541.

28. Ichii O, Hosotani M, Masum MA, Horino T, Otani Y, Namba T, et al. Close Association between Altered Urine-Urothelium Barrier and Tertiary Lymphoid Structure Formation in the Renal Pelvis during Nephritis. J Am Soc Nephrol. 2022; 33: 88–107.

29. Hamade A, Li D, Tyryshkin K, Xu M, Conseil G, Yolmo P, et al. Sex differences in the aging murine urinary bladder and influence on the tumor immune microenvironment of a carcinogen-induced model of bladder cancer. Biol Sex Differ. 2022; 13: 19.

30. N J, J T, Sl N, Gt B. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies. Oncoimmunology. 2021; 10: 1900508.

31. Ng KW, Boumelha J, Enfield KSS, Almagro J, Cha H, Pich O, et al. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature. 2023; 616: 563–573.

32. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020; 577: 549–555.

33. Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun C, Calderaro J, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020; 577: 556–560.

34. Delvecchio FR, Goulart MR, Fincham R, Bombadieri M, Kocher HM. B cells in pancreatic cancer stroma. World J Gastroentero. 2022; 28: 1088–1101.

35. Weinstock JS, Gopakumar J, Burugula BB, Uddin MM, Jahn N, Belk JA, et al. Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis. Nature. 2023; 616: 755–763.

36. Oberbeck S, Schrader A, Warner K, Jungherz D, Crispatzu G, von Jan J, et al. Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. Blood. 2020; 136: 2786–2802.

37. Sun S, Fang W. Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene. Biomed Pharmacother. 2020; 126: 110107.

38. Ho M, Lummertz Da Rocha E, Zhang C, Ingle JN, Goss PE, Shepherd LE, et al. TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factorκ B p65: Single Nucleotide Polymorphism and Estrogen Dependence. J Pharmacol Exp Ther. 2018; 365: 700–710.

39. Lu H, Dai W, Guo J, Wang D, Wen S, Yang L, et al. High Abundance of Intratumoral γδ T Cells Favors a Better Prognosis in Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis. Front Immunol. 2020; 11: 573920.

40. Cabrita R, Lauss M, Sanna A, Donia M, Skaarup LM, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020; 577: 561–565.

41. Schriek P, Ching AC, Moily NS, Moffat J, Beattie L, Steiner TM, et al. Marginal zone B cells acquire dendritic cell functions by trogocytosis. Science. 2022; 375: eabf7470.

42. Groeneveld CS, Fontugne J, Cabel L, Bernard-Pierrot I, Radvanyi F, Allory Y, et al. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. Eur J Cancer. 2021; 148: 181–189.

43. Horeweg N, Workel HH, Loiero D, Church DN, Vermij L, Léon-Castillo A, et al. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nat Commun. 2022; 13: 1373.

44. Dai S, Zeng H, Liu Z, Jin K, Jiang W, Wang Z, et al. Intratumoral CXCL13 + CD8 + T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma. J Immunother Cancer. 2021; 9: e001823.

45. Stachelscheid J, Jiang Q, Aszyk C, Warner K, Bley N, Muller T, et al. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL. Blood. 2023; 141: 1425–1441.

46. Jiang X, Wang Y, Li X, He L, Yang Q, Wang W, et al. Microarray profile of B cells from Graves’ disease patients reveals biomarkers of proliferation. Endocr Connect. 2020; 9: 405–417.

47. Fiorenza MT, Rava A. The TCL1 function revisited focusing on metabolic requirements of stemness. Cell Cycle (Georgetown, Tex.). 2019; 18: 3055–3063.

48. Wei Y, Huang CX, Xiao X, Chen DP, Shan H, He H, et al. B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments. Oncogene. 2021; 40: 4737–4745.

49. Fridman WH, Meylan M, Petitprez F, Sun C, Italiano A, Sautès-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nature Reviews. Clinical Oncology. 2022; 19: 441–457.

50. Lauss M, Donia M, Svane IM, Jonsson G. B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy? Clin Cancer Res. 2022; 28: 1751–1758.

51. Laumont CM, Nelson BH. B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell. 2023; 41: 466–489.

52. Sharma R, Smolkin RM, Chowdhury P, Fernandez KC, Kim Y, Cols M, et al. Distinct metabolic requirements regulate B cell activation and germinal center responses. Nat Immunol. 2023; 24: 1358–1369.

53. Xia J, Xie Z, Niu G, Lu Z, Wang Z, Xing Y, et al. Single-cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer. Immunology. 2023; 168: 135–151.

54. Jin H, Kong Z, Jiang B, Tu M, Xu J, Cheng J, et al. Identification and Characterization of chCR2, a Protein That Binds Chicken Complement Component 3d. The Journal of Immunology. 2023; 210: 1408–1418.

55. He M, He Q, Cai X, Liu J, Deng H, Li F, et al. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer. J Immunother Cancer. 2023; 11: e005539.

56. Ukita M, Hamanishi J, Yoshitomi H, Yamanoi K, Takamatsu S, Ueda A, et al. CXCL13-producing CD4 + T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. Jci Insight. 2022; 7: e157215.

57. Ebrahimi N, Abdulwahid A, Mansouri A, Karimi N, Bostani RJ, Beiranvand S, et al. Targeting the NF-kappaB pathway as a potential regulator of immune checkpoints in cancer immunotherapy. Cell Mol Life Sci. 2024; 81: 106.

58. Chang Y, Hsu Y, Wu T, Huang C, Liou L, Chiu Y, et al. Regulation of estrogen receptor α function in oral squamous cell carcinoma cells by FAK signaling. Endocr-Relat Cancer. 2014; 21: 555–565.

59. Boccellino M, Di Stasio D, Dipalma G, Cantore S, Ambrosio P, Coppola M, et al. Steroids and growth factors in oral squamous cell carcinoma: useful source of dental-derived stem cells to develop a steroidogenic model in new clinical strategies. Eur Rev Med Pharmaco. 2019; 23: 8730–8740.